Danielle Brill
Stock Analyst at Truist Securities
(3.79)
# 733
Out of 5,044 analysts
88
Total ratings
43.42%
Success rate
12.31%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $459 → $535 | $481.59 | +11.09% | 2 | Oct 17, 2025 | |
| IMVT Immunovant | Initiates: Hold | $16 | $21.65 | -26.10% | 5 | Oct 14, 2025 | |
| UPB Upstream Bio | Initiates: Buy | $47 | $24.19 | +94.30% | 1 | Oct 14, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $56 | $33.82 | +65.58% | 1 | Oct 14, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $56 → $80 | $75.17 | +6.43% | 2 | Oct 2, 2025 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $417.21 | - | 3 | Sep 3, 2025 | |
| IRON Disc Medicine | Initiates: Buy | $86 | $85.00 | +1.18% | 6 | Jul 21, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $29.32 | +63.71% | 8 | Jul 21, 2025 | |
| TECX Tectonic Therapeutic | Initiates: Buy | $64 | $18.62 | +243.72% | 2 | Jul 21, 2025 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $163 | $138.02 | +18.10% | 6 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $66 | $66.62 | -0.93% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $23.98 | +25.10% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $18.85 | +27.32% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $70.59 | -26.34% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $16.25 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $51.86 | +52.33% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $12.84 | +40.19% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $23.45 | +539.66% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $147.86 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $821.97 | -26.40% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $22.53 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $42.30 | +18.20% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $41.96 | +21.54% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $7.43 | +1,245.90% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $67.35 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.91 | - | 5 | Jun 27, 2023 |
Alnylam Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $459 → $535
Current: $481.59
Upside: +11.09%
Immunovant
Oct 14, 2025
Initiates: Hold
Price Target: $16
Current: $21.65
Upside: -26.10%
Upstream Bio
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $24.19
Upside: +94.30%
Dianthus Therapeutics
Oct 14, 2025
Initiates: Buy
Price Target: $56
Current: $33.82
Upside: +65.58%
Palvella Therapeutics
Oct 2, 2025
Maintains: Buy
Price Target: $56 → $80
Current: $75.17
Upside: +6.43%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $417.21
Upside: -
Disc Medicine
Jul 21, 2025
Initiates: Buy
Price Target: $86
Current: $85.00
Upside: +1.18%
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $29.32
Upside: +63.71%
Tectonic Therapeutic
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $18.62
Upside: +243.72%
Neurocrine Biosciences
Jul 21, 2025
Initiates: Buy
Price Target: $163
Current: $138.02
Upside: +18.10%
Jul 21, 2025
Initiates: Buy
Price Target: $66
Current: $66.62
Upside: -0.93%
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $23.98
Upside: +25.10%
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $18.85
Upside: +27.32%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $70.59
Upside: -26.34%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $16.25
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $51.86
Upside: +52.33%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $12.84
Upside: +40.19%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $23.45
Upside: +539.66%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $147.86
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $821.97
Upside: -26.40%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $22.53
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $42.30
Upside: +18.20%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $41.96
Upside: +21.54%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $7.43
Upside: +1,245.90%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $67.35
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $10.91
Upside: -